Equities

Rockwell Medical Inc

Rockwell Medical Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)4.02
  • Today's Change0.08 / 2.03%
  • Shares traded477.70k
  • 1 Year change+100.00%
  • Beta1.4294
Data delayed at least 15 minutes, as of Sep 18 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Rockwell Medical, Inc. is a healthcare company. The Company develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers around the world. The Company operates in the hemodialysis market, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceuticals, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. It is the supplier of life-sustaining hemodialysis concentrates products to dialysis clinics. Its hemodialysis concentrates products are used to sustain a patient's life by removing toxins and balancing electrolytes in a dialysis patient’s bloodstream. The Company manufactures hemodialysis concentrates at its facilities in Michigan, South Carolina, and Texas, and the Company manufactures its dry acid concentrate mixers at its facility in Iowa.

  • Revenue in USD (TTM)94.37m
  • Net income in USD-4.77m
  • Incorporated2019
  • Employees237.00
  • Location
    Rockwell Medical Inc30142 WIXOM ROADWIXOM 48393United StatesUSA
  • Phone+1 (248) 960-9009
  • Fax+1 (302) 655-5049
  • Websitehttps://www.rockwellmed.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Marinus Pharmaceuticals Inc30.26m-149.24m85.38m165.00------2.82-2.66-2.660.5391-0.86140.210.75086.98183,412.10-103.54-49.64-131.60-57.7690.64---493.14-518.962.15-11.806.10--21.63---613.59--7.47--
I-Mab ADR-100.00bn-100.00bn88.16m220.00--0.3751----------2.91-----------35.51---41.43-------509.54----0.00--111.86-13.6544.45---5.95--
Zhong Yuan Bio-Technology Holdings Ltd2.49m232.02k88.22m35.00391.37348.44--35.380.0128-0.01760.13950.01430.8583-1.613.2571,253.436.49--19.10--106.30--7.57--0.83092.530.8593---28.60---148.37------
CASI Pharmaceuticals Inc23.10m-27.21m92.34m176.00--10.24--4.00-2.03-2.031.720.67310.35770.89172.39131,250.00-41.56-34.75-62.38-46.9156.8155.98-116.17-153.722.36--0.6718---21.41--34.27--14.65--
Rockwell Medical Inc94.37m-4.77m119.44m237.00--5.20--1.27-0.169-0.1693.210.75732.0713.9711.61398,194.10-10.48-46.29-16.25-65.3813.444.66-5.06-36.511.60-1.840.3144--14.845.6954.82--76.21--
Assertio Holdings Inc132.19m-345.11m123.94m53.00--0.9378--0.9376-4.11-4.111.441.390.38621.273.242,494,076.00-100.82-21.51-134.56-32.0572.1288.68-261.08-62.101.51--0.2266---2.67-13.38-402.80---28.25--
LifeVantage Corp200.16m2.94m124.79m217.0044.494.8119.150.62350.22480.224815.512.083.172.6687.77922,414.804.659.956.9515.5579.3081.451.473.081.01--0.0026.95-6.20-2.4015.63-16.94-2.18--
OptiNose Inc75.06m-40.91m129.67m132.00------1.73-0.3479-0.34790.6195-0.28630.63090.79093.50568,621.20-34.39-48.25-199.84-98.9589.9286.96-54.50-131.663.59-0.85371.52---6.9358.6452.58---27.96--
Global Pharmatech Inc.3.18m-2.24m138.32m217.00--1.02--43.51-0.0964-0.09640.13670.34280.22921.593.5714,649.77-16.44---22.55--46.21---71.75--1.62-9.870.2223--32.43---142.03------
Elutia Inc24.99m-70.10m139.99m54.00------5.60-3.05-2.861.12-2.280.53032.325.08462,722.20-148.77-42.93-1,212.93-79.3442.4643.32-280.53-64.160.6842-0.6561-----49.69-8.71-25.39--12.74--
Hongchang International Co Ltd4.65m-292.22k140.08m8.00--3.57--30.13-0.0006-0.00060.00930.07570.16475.028.74---0.8827-7.98-0.9331-10.943.9211.47-5.36-64.883.77--0.2642--3,289.22---42.63------
Eton Pharmaceuticals Inc31.38m-6.69m147.78m30.00--10.94--4.71-0.2596-0.25961.220.52291.008.827.891,046,033.00-21.31-46.22-38.27-58.2059.4872.16-21.31-76.861.28--0.2571--48.90--89.62--26.85--
Biostem Technologies Inc131.44m7.87m155.99m67.0028.628.6119.301.190.33460.33467.311.112.807.413.35--16.78--107.11--94.73--5.98--1.2015.520.2012--------------
Lifecore Biomedical Inc128.26m9.33m156.81m524.0034.2513.718.621.220.14820.23183.831.760.50552.144.26244,774.803.68-5.914.35-8.3332.6331.017.27-19.161.060.23730.6923--24.20-25.46114.5334.47-16.72--
Data as of Sep 18 2024. Currency figures normalised to Rockwell Medical Inc's reporting currency: US Dollar USD

Institutional shareholders

19.06%Per cent of shares held by top holders
HolderShares% Held
Armistice Capital LLCas of 30 Jun 20243.22m10.38%
The Vanguard Group, Inc.as of 30 Jun 20241.12m3.59%
Perkins Capital Management, Inc.as of 30 Jun 2024350.41k1.13%
Geode Capital Management LLCas of 30 Jun 2024305.35k0.98%
Richmond Brothers, Inc.as of 30 Jun 2024276.83k0.89%
BlackRock Fund Advisorsas of 30 Jun 2024212.66k0.69%
GSA Capital Partners LLPas of 30 Jun 2024181.36k0.58%
Renaissance Technologies LLCas of 30 Jun 2024102.70k0.33%
SSgA Funds Management, Inc.as of 30 Jun 202478.20k0.25%
Citadel Securities LLCas of 30 Jun 202470.15k0.23%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.